MD Anderson Cancer Center

Houston, Texas

On January 12, 2019, founder and president, Ben Broghammer, formally presented our gift to MD Anderson, pictured with Dr. Naruhiko Ikoma, MD, MS, who is one of three physicians leading the gastric cancer research program at the center.

On January 12, 2019, founder and president, Ben Broghammer, formally presented our gift to MD Anderson, pictured with Dr. Naruhiko Ikoma, MD, MS, who is one of three physicians leading the gastric cancer research program at the center.

We are thrilled to announce the third cancer center and research program we are helping to financially support! The University of Texas, MD Anderson Cancer Center is a leader in the fight back against cancer, and through groundbreaking research, experts MD Anderson have pioneered many improvements in treating stomach cancer. Their physicians have led some of the largest international studies on chemotherapy for stomach cancer, and they continue to explore new, more advanced treatments. With a treatment approach focused on improving both outcomes and quality of life for patients, they have built several programs in gastric cancer focused on MD Anderson’s core values of caring and discovery.

On January 12, 2019, founder and president, Ben Broghammer, formally presented our gift to MD Anderson, pictured with Dr. Naruhiko Ikoma, MD, MS, who is one of three physicians leading the gastric cancer research program at the center.

About MD Anderson

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. Located in Houston, TX, MD Anderson has changed the world by bringing life-saving innovation from research labs into the homes and hearts of millions, for the past 75 years. 

Mission

The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. 

About the Program

Neoadjuvant Therapies

Due to the difficulty in administering chemotherapy or radiation after major abdominal surgery, they continue to make strides in finding better ways to provide cancer treatment prior to surgery. MD Anderson is a leader in the investigation of preoperative chemotherapy and radiation for patients with gastric cancer. They have the nation’s largest cohort of patients treated with chemoradiation therapy prior to surgery, and their current studies of outcomes associated with this approach provide an educational resource for national and international colleagues.

Clinical Trials

Since MD Anderson is one of the nation’s leading research centers, they have the expertise and experience to offer clinical trials (research studies) of new treatments for every type and stage of stomach cancer. For example:

  • Recently completed the first trial in the U.S. to use heated intraperitoneal chemotherapy to treat patients with gastric cancer that has spread outside the stomach.

  • They have just completed a Phase I trial — the first in the U.S. — using minimally invasive heated intraperitoneal chemotherapy.

  • They are leading the world’s first trial of three-drug chemotherapy for gastric cancer.

  • Their ongoing study of debulking surgery, gastrectomy and heated intraperitoneal chemotherapy will represent the first completed trial of this technique in the U.S.

Hereditary Cancer

Their program in treating patients with hereditary gastric cancer has established us as a center of excellence. They have treated more than 50 families with CDH1 mutations, which are associated with high risk of a rare type of stomach cancer called hereditary diffuse gastric cancer. Their most recent initiative has been the introduction of laparoscopic and minimally invasive gastrectomy for patients with gastric cancer.

Palliative Care

For advanced gastric cancer patients with malignant bowel obstruction, they have developed the MD Anderson Symptom Inventory for Gastrointestinal Obstruction — the first patient-reported outcome measure for clinical and research use. They have just completed a study using this outcome measure to assess symptom severity and quality of life in patients with stage IV disease.

Our Statement

December 28, 2018

Three and a half years ago, this foundation was started for a simple purpose.  To fund research for and to chip away at one of the biggest problems our world is facing—cancer.  If were able to help just one person and make a difference in the world, no matter how big or small that was, we would have accomplished what we set out to do. 

Over the past few years, we have surpassed that dream, time and time again, touching the lives of countless people around the world, and we have been able to help support two programs and cancer centers, furthering research for gastric cancer, and contributing to work that one day, will find a cure.

And today, we are thrilled to announce a third.  The University of Texas MD Anderson Cancer Center, in Houston.

The ground-breaking work being conducted there by experts and physicians is paving the way for gastric cancer research and focuses on improving both outcomes and quality of life.  Their physicians have led some of the largest international studies on chemotherapy for the disease, and they continue to explore new, more advanced treatment options.

We started with the dream of helping others and making our world a better, brighter, and cancer free place.  Today, that dream is being realized, once again, and we are taking yet another step forward in bringing our world closer to the day a cure for cancer is found.

We are so proud of everything we have been able to do, and we know we haven’t done it alone.  To everyone who made this milestone possible, THANK YOU! You have made us who we are today, and your generosity is allowing us to continue forward. Together, we are paving the way for a better world, and one that is cancer free.

Thank you!